CA2185616A1 - Hormonal agent for skin treatment - Google Patents

Hormonal agent for skin treatment

Info

Publication number
CA2185616A1
CA2185616A1 CA002185616A CA2185616A CA2185616A1 CA 2185616 A1 CA2185616 A1 CA 2185616A1 CA 002185616 A CA002185616 A CA 002185616A CA 2185616 A CA2185616 A CA 2185616A CA 2185616 A1 CA2185616 A1 CA 2185616A1
Authority
CA
Canada
Prior art keywords
dienogest
skin
androstandiol
glucuronide
moderate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185616A
Other languages
French (fr)
Other versions
CA2185616C (en
Inventor
Siegfried Golbs
Michael Oettel
Michael Dittgen
Thomas Graser
Christoph Luderschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Siegfried Golbs
Michael Oettel
Michael Dittgen
Thomas Graser
Christoph Luderschmidt
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried Golbs, Michael Oettel, Michael Dittgen, Thomas Graser, Christoph Luderschmidt, Jenapharm Gmbh filed Critical Siegfried Golbs
Publication of CA2185616A1 publication Critical patent/CA2185616A1/en
Application granted granted Critical
Publication of CA2185616C publication Critical patent/CA2185616C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin. The pharmaceutical preparation including the dienogest and conventional dermatologically acceptable carrier and auxiliary substances in the described galenic formulation advantageously provides a drastic reduction in androstandiol glucuronide and moderate androgen receptor blockage without passing through the skin barrier so that systemic effects including side reactions are substantially prevented.
CA002185616A 1995-09-15 1996-09-16 Hormonal agent for skin treatment Expired - Fee Related CA2185616C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19534209A DE19534209A1 (en) 1995-09-15 1995-09-15 Hormonal agent for the treatment of the skin
DE19534209.7 1995-09-16

Publications (2)

Publication Number Publication Date
CA2185616A1 true CA2185616A1 (en) 1997-03-17
CA2185616C CA2185616C (en) 2001-02-27

Family

ID=7772237

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185616A Expired - Fee Related CA2185616C (en) 1995-09-15 1996-09-16 Hormonal agent for skin treatment

Country Status (4)

Country Link
US (1) US5910493A (en)
EP (1) EP0765663A3 (en)
CA (1) CA2185616C (en)
DE (1) DE19534209A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488940B2 (en) 1997-08-21 2002-12-03 Johnson & Johnson Consumer Companies, Inc. Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
BR9811963A (en) * 1997-08-21 2002-02-05 Johson & Johnson Consumer Comp Use of 17-alpha-estradiol for the treatment of aged or sun-damaged skin and / or skin atrophy
WO2000018362A1 (en) * 1998-09-28 2000-04-06 Petersen, Sharleen, Caron Hair growth stimulant
DE19916384A1 (en) * 1999-03-31 2000-10-05 Schering Ag Microparticles useful in treatment of androgen-dependent disorders include biodegradable, synthetic polymers of e.g. polyesters of hydroxycarboxylic acids
WO2000062753A1 (en) * 1999-04-16 2000-10-26 Jenapharm Gmbh & Co. Kg Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
DE19918644A1 (en) * 1999-04-16 2000-10-26 Jenapharm Gmbh Intradermal composition for local treatment of skin aging or wrinkles, comprising matrix containing estrogen and structure former to minimize systemic side-effects
DE10141443B4 (en) * 2001-08-23 2007-02-01 Christos C. Prof. Dr. Zouboulis Use of molecular biologically produced, non-viral agents for the treatment of acne
ATE419037T1 (en) * 2002-09-04 2009-01-15 Fraunhofer Ges Forschung USE OF AN AGENT FOR THE THERAPY OF CARDIAC HYPERTROPHY
AU2005214167B2 (en) * 2004-02-13 2008-08-07 Warner-Lambert Company Llc Androgen receptor modulators
CA2563291A1 (en) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc 4-cyano-phenoxy-alkyl carboxyl derivatives as androgen modulators
CA2562672C (en) * 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
BRPI0513020A (en) * 2004-07-08 2008-04-22 Warner Lambert Co androgen modulators, their uses, pharmaceutical composition, topical pharmaceutical formulation and article of manufacture
US20080064745A1 (en) * 2004-08-18 2008-03-13 Warner-Lambert Company Llc Androgen Modulators
US20060118002A1 (en) * 2004-12-03 2006-06-08 Sud-Chemie Inc. Organoclay composition containing quat mixtures
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US20090170886A1 (en) * 2005-08-08 2009-07-02 Pfizer Inc Androgen modulators
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
DE102006062120A1 (en) 2006-12-22 2008-06-26 Grünenthal GmbH Pharmaceutical composition for acne treatment
US8846063B2 (en) * 2008-12-16 2014-09-30 Kimberly-Clark Worldwide, Inc. Personal care composition containing a volatile and a terpene alcohol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2257223A1 (en) * 1972-11-22 1974-06-12 Fouad Dr Med Talabani Hair growth and anti- hairloss compsn. - contg. mixts of androgen, oestrogen, corticoid and carriers
DE4229820C2 (en) * 1992-09-07 1998-12-03 Jenapharm Gmbh Progestogen-based pharmaceutical preparation
DE4308406C1 (en) * 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4313926A1 (en) * 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception
DE4321957C2 (en) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Use of a hormonal agent to treat acne
DE4406462C2 (en) * 1994-02-24 1997-05-28 Jenapharm Gmbh Process and apparatus for the preparation of solid dispersions

Also Published As

Publication number Publication date
DE19534209A1 (en) 1997-03-20
CA2185616C (en) 2001-02-27
EP0765663A3 (en) 1997-11-12
US5910493A (en) 1999-06-08
EP0765663A2 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
CA2185616A1 (en) Hormonal agent for skin treatment
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
ITMI961152A0 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE INGREDIENT, ESTROGEN OR PROGESTIN OR MIXTURES THEREOF
AU6029096A (en) Compositions and methods for topical administration of pharm aceutically active agents
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
CA2275889A1 (en) Formulation and method for treating neoplasms by inhalation
FR2728793B1 (en)
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
WO2000007979A3 (en) Compounds and compositions for delivering active agents
CA2214884A1 (en) Poly(hydroxy acid)/polymer conjugates for skin applications
EP0841936A4 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
CA2181742A1 (en) Reduction of skin irritation during electrotransport delivery
CA2265461A1 (en) Compositions and methods for topical application of therapeutic agents
CA2254079A1 (en) Androstene derivatives
CA2093349A1 (en) Composition containing steroid derivatives
ZA94413B (en) Pharmaceutical formulation for the treatment of nicotine dependence
AU5347596A (en) External preparations for treating dermatoses
HUT64082A (en) Process for producing steroid derivatives and pharmaceutical compositions comprising same as active ingredient
EP0754457A4 (en) Antiobestic agent
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
WO2001085139A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
AU4262599A (en) Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
PL348202A1 (en) Pharmaceutically active composition and dispensing device

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed